300 related articles for article (PubMed ID: 20849866)
21. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.
Wiley JL; Breivogel CS; Mahadevan A; Pertwee RG; Cascio MG; Bolognini D; Huffman JW; Walentiny DM; Vann RE; Razdan RK; Martin BR
Eur J Pharmacol; 2011 Jan; 651(1-3):96-105. PubMed ID: 21114999
[TBL] [Abstract][Full Text] [Related]
22. Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ(9)-tetrahydrocannabinol in the rat.
Craft RM; Kandasamy R; Davis SM
Pain; 2013 Sep; 154(9):1709-1717. PubMed ID: 23707295
[TBL] [Abstract][Full Text] [Related]
23. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat.
Dyson A; Peacock M; Chen A; Courade JP; Yaqoob M; Groarke A; Brain C; Loong Y; Fox A
Pain; 2005 Jul; 116(1-2):129-37. PubMed ID: 15936883
[TBL] [Abstract][Full Text] [Related]
24. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
Bolognini D; Cascio MG; Parolaro D; Pertwee RG
Br J Pharmacol; 2012 Apr; 165(8):2561-74. PubMed ID: 21615724
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
26. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
27. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
[TBL] [Abstract][Full Text] [Related]
28. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed.
Duncan M; Kendall DA; Ralevic V
J Pharmacol Exp Ther; 2004 Oct; 311(1):411-9. PubMed ID: 15205450
[TBL] [Abstract][Full Text] [Related]
29. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice.
Curto-Reyes V; Boto T; Hidalgo A; Menéndez L; Baamonde A
Eur J Pharmacol; 2011 Oct; 668(1-2):184-9. PubMed ID: 21771590
[TBL] [Abstract][Full Text] [Related]
30. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
31. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.
Raborn ES; Cabral GA
J Pharmacol Exp Ther; 2010 Apr; 333(1):319-27. PubMed ID: 20089805
[TBL] [Abstract][Full Text] [Related]
33. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
Fox A; Kesingland A; Gentry C; McNair K; Patel S; Urban L; James I
Pain; 2001 May; 92(1-2):91-100. PubMed ID: 11323130
[TBL] [Abstract][Full Text] [Related]
34. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
35. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models.
Vincenzi F; Targa M; Corciulo C; Tabrizi MA; Merighi S; Gessi S; Saponaro G; Baraldi PG; Borea PA; Varani K
Pain; 2013 Jun; 154(6):864-73. PubMed ID: 23518609
[TBL] [Abstract][Full Text] [Related]
36. Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.
Gonsiorek W; Lunn CA; Fan X; Deno G; Kozlowski J; Hipkin RW
Br J Pharmacol; 2007 Aug; 151(8):1262-71. PubMed ID: 17603556
[TBL] [Abstract][Full Text] [Related]
37. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
Lichtman AH; Martin BR
Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
39. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]